• Journal of Chest Surgery
• /
• 제29권9호
• /
• pp.1031-1035
• /
• 1996

폐의 편평상피암종에서 기관지표면상피의 화생에 대해서는 많은 이들에 의해서 밝혀진 바 있지만 그 외의 다른 종류의 폐암과 연관된 기관지 표면상피의 변화에 대해서는 그 예가 많지 않고 소세포폐암종에 대해서는 더욱 그러하다. 한편 소세포암종의 조직학적 분류와그아형에 대해서 지난수십년 간많은 관심이 모아져 왔다. 이 종량의 아형을분류하는기본적인 근거는 그 형태학적 판정 기준에 있다. 1967년 WHO폐암종 분류법이 제긍된 이후 3여러 기관에서 SCLC의 임상경과나 치료에 대한 반응, 그 아형을 연구하였다. 1988년 IASLC에서는 소세포암종을 그 형태학적 구분으로 세가지 아형 : Small cell carcinoma (2) Mixed small cel1/1arge ceil carcinoma (3) Combined small cell carcinoma로 분류하고 예후와 치료에 대한 반응의 차이에 대해서 언급하였다. 최근 저자들은 68세 남자환자에서 소세포암종에서 국소적으로 편평양분화를 보이는 세포가 함께 혼합되어 있는 주종괴와 분리되 어서 존재하는 기관지 상피세포에 편평상피암종이 동반된 예를 전폐 절제 술을 하고 조직 검사상 경험하였기에 문헌고찰과 함께 보고하는 바이다.

• Tuberculosis and Respiratory Diseases
• /
• 제82권3호
• /
• pp.211-216
• /
• 2019

Background: Docetaxel is one of the standard treatments for advanced non-small cell lung cancer. Docetaxel is usually administered in a 3-week schedule, but there is significant toxicity. In this phase II clinical study, we investigated the efficacy and safety of a 4-weekly schedule of docetaxel monotherapy, as first-line chemotherapy for advanced squamous cell carcinoma in elderly lung cancer patients. Methods: Patients with stage IIIB/ IV lung squamous-cell carcinoma age 70 or older, that had not undergone cytotoxic chemotherapy were enrolled. Patients received docetaxel $25mg/m^2$ on days 1, 8, and 15, every 4 weeks. Primary endpoint was the objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity profiles. Results: A total of 19 patients were enrolled. Among 19 patients, 17 were for evaluated efficacy and safety. In the intent-to-treat population, ORR and disease control rate (DCR) were 11.8% and 47.1%, respectively. In the response evaluable population, ORR was 16.7% and DCR was 66.7%. Median PFS and OS were 3.1 months and 3.3 months, respectively. There were three adverse grade 3/4 events. Grade 1 neutropenia was reported in one patient. Conclusion: Our data failed to demonstrate efficacy of a 4-weekly docetaxel regimen, in elderly patients with a poor performance status. However, incidence of side effects, including neutropenia, was lower than with a 3-week docetaxel regimen, as previously reported.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권14호
• /
• pp.5945-5950
• /
• 2014

Objectives: To retrospectively review the safety and clinical efficacy of bevacizumab concomitant with chemotherapy in Chinese patients with advanced non-squamous non-small cell lung cancer (NSNSCLC). Methods: Clinical data for 79 patients with NSNSCLC who received bevacizumab concomitant with chemotherapy in Chinese PLA General Hospital from April 28th 2009 to May 5th 2013 were retrospectively reviewed to analyze the clinical efficacy including disease control rate (DCR), overall response rate (ORR), progression-free survival (PFS), overall survival (OS), the Eastern Cooperative Oncology Group (ECOG) score and the safety. Results: The Eastern Cooperative Oncology Group (ECOG) score was 0-2. By the final cutoff date (June 9, 2013), 54 (68.4%) patients had disease progression and 37 (46.8%) died. The ORR was 32.9% and the DCR was 83.5%. The ORR of the first-, second-, and third- or later-line treatments were 51.4%, 25.0% and 12.5%, while the DCR were 94.3%, 80.0% and 70.8%, respectively. The median OS (mOS) and PFS (mPFS) were 13.5 and 5.83 months, respectively. The mOS of patients with the first-, second-, and third- or later- line treatments were 16.2, 10.9 and 8.30 months, while the mPFS were 7.27, 5.90 and 5.17 months, respectively. Chemotherapy-related adverse events included myelosuppression, vomiting, hepatic dysfunction and renal dysfunction, while the common serious bevacizumab-related adverse events were thromboembolic problems, gastrointestinal perforation and reversible posterior leukoencephalopathy syndrome, which could be well managed. Conclusions: Bevacizumab concomitant with chemotherapy is effective and the related toxicity can be well tolerated in Chinese patients with NSNSCLC.

• Journal of Chest Surgery
• /
• 제33권1호
• /
• pp.68-72
• /
• 2000

Background: The resection of recurrent non-small cell lung cancer can be performed very rarely. There has been many arguments for longterm result and therapeutic role in surgical management of recurrent non-small cell lung cancer(NSCLC). We analyze our result of surgical re-resection of recurrent NSCLC for 10 years retrospectively. Material and Method: In the period from 1987 to 1997, 702 patients who had been confirmed for NSCLC had undergone complete resection in Seoul National University Hospital. As December 1997, 22 of these patients have been operated on the diagnosis of recurrent lung cancer. In these patients one has revealed for benign nodule at postoperative pathologic pathologic was unresectable. and two had revealed other cell type on postoperative pathologic examination. Analysis about postoperative survival rate and the factors that influence postoperative survival rate - sex, age, pathologic stage, cell type, operation adjuvant therapy after first and second operation location of recurrence disease free survival-was 59.1$\pm$10.9 year. There were 14 men and 3 women. Four patients was received radiation therpy after first opration and two patients was received postoperative chemotherapy. At first operation 2 patients was stage Ia, 8 was stage Ib, 1 was stage IIa 6 was stage IIb. Eleven patients had squamous. cell carcinoma at postoperatrive pathologic examination five had adenocarcinoma and one had bronchioalveolar carcinoma. In second operation 8 patients were received limited resection. 9 were received lobectomy or pneumonectomy. One-year survival rate was 82.4% and five-year survival rate was 58.2% Non-adjuvant therapy group after initial operation was more survived than adjuvant therapy group statistically. Conclusion: operation was more survived than adjuvant therapy group statistically. Conclusion : Operation was feasible treatment modality for re-resectable non-small cell lung cancer. But we cannot rule out possibility of double primary lung cancer for them. Postoperative prognostic factor was adjuvant therapy or nor after first oepration but further study of large scale is needed for stastically more valuable result.

• Tuberculosis and Respiratory Diseases
• /
• 제42권2호
• /
• pp.149-155
• /
• 1995

연구목적: Cytokeratin 19는 기관지의 상피세포와 같은 단순 또는 가중층상피세포에 국한된 40KD의 산성 분자로 면역조직학적 검사를 통해 cytokeratin 19가 폐암 조직에서 많이 발현되는 것으로 알려져 있다. Cytokeratin 19에 특징적인 단일 클론 항체 BM 19-21과 KS 19-1을 이용한 면역방사계수법, CYFRA 21-1을 이용하여 cytokeratin 19분절이 폐암 특히 편평상피세포암의 진단에 유용한 표지자가 될 수 있다는 보고가 있어 폐암 표지자로서 CYFRA 21-1의 유용성을 조사해 보기 위하여 본 연구를 하였다. 방법: 저자 등은 영남대학교 의과대학 부속병원 내과에 1993년 4월부터 1994년 8월까지 입원한 원발성 폐암 환자 39명(편평상피 세포암 19명, 선암 11명, 소세포암 9명)을 폐암군으로, 비악성 호흡기질환자 15명(폐결핵 8명, 만성 폐색성 폐질환 3명, 폐렴 2명, 만성 폐색성 폐질환과 폐결핵이 동반된 환자 2명)을 대조군으로 하여 새로운 폐암 표지자의 가능성이 있는 CYFRA 21-1의 유용성을 조사하였다. CYFRA 21-1의 측정은 면역방사계수측정 kit인 ELSA-CYFRA 21-1을 사용하였다. 결과: 폐암의 조직학적 분류에 따른 CYFRA 21-1의 혈중 측정치는 편평상피세포암이 $20.2{\pm}4.7ng/ml$, 선암이 $7.2{\pm}1.6ng/ml$, 비소세포암이 $15.5{\pm}4.7ng/ml$로 모두 대조군의 $1.7{\pm}0.5ng/ml$보다 유의하게 증가되어 있었다(p<0.01). 또한 비소세포암중 편평상피세포암에서 선암보다 유의하게 증가되어 있었다(p<0.05). 그러나 소세포암에서는 $2.9{\pm}0.9ng/ml$로 대조군과 유의한 차이가 없었다. CYFRA 21-1의 정상 범위를 3.3ng/ml 이내로 하였을때 소세포암에서는 민감도 11.1%, 특이도 65.2% 였으나, 비소세포암에서는 민감도 70.0%, 특이도 62.5%였고 이 중 편평상피 세포암인 경우 민감도 73.7%, 특이도 75%였으며 선암인 경우 63.6%, 78.9%로 산출되었다. 결론: CYFRA 21-1은 비소세포암의 종양 표지자로 유용성이 있을 것으로 생각되며, 특히 편평상피 세포암의 진단에 도움이 될 것으로 생각되었다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권12호
• /
• pp.7295-7300
• /
• 2013

Lung cancer is the most common cause of cancer-related death in the world. The main types are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC), the latter including squamous cell carcinoma (SCC), adenocarcinoma and large cell carcinoma. NSCLCs account for about 80% of all lung cancer cases. Microcephalin (MCPH1), also called BRIT1 (BRCT-repeat inhibitor of hTERT expression), plays an important role in the maintenance of genomic stability. Recently, several studies have provided evidence that the expression of MCPH1 gene is decreased in several different types of human cancers. We evaluated the expression of protein MCPH1 in 188 lung cancer and 20 normal lung tissues by immunohistochemistry. Positive MCPH1 staining was found in all normal lung samples and only some cancerous tissues. MCPH1-positive cells were significantly lower in lung carcinoma compared with normal tissues. Furthermore, we firstly found that MCPH1 expression in lung adenocarcinoma is higher than its expression in squamous cell carcinoma. Change in MCPH1 protein expression may be associated with lung tumorigenesis and may be a useful biomarker for identification of pathological types of lung cancer.

• Radiation Oncology Journal
• /
• 제6권1호
• /
• pp.35-39
• /
• 1988

From Jan.1984 to Dec. 1986, 90 patients with lung cancer were treated at the Department of Radiation Therapy in Hanyang University Hospital. Histopathologically, 67 cases of them were the squamous cell carcinoma,7 cases were the adenocarcinoma, 4 cases were the large cell undiffe rentiated carcinoma and 12 cases were the small cell carcinoma. Among the 78 patients with non small cell carcinoma, 50 patients had received radiation dosage above 4000 cGy.40 patient had follow up from 17 months to 53 months. The complete response rate was $7.3\%$ and partial response rate was $68.3\%$. Overall survival at 1, 2 and 3 years were $47.5\%,\;23.5\%\;and\;6.3\%$ respectively. None was survived longer than 38 months. Median survival was 12.2 month for 40 patient and 9 month for stage III, M1 group and 9.5 month for stage III, MO group. In M1 patient no survival was seen after 2 years while in M0 patient $23.3\%$ survival was seen.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권4호
• /
• pp.1477-1482
• /
• 2012

Squamous cell carcinoma and adenocarcinoma are the major histological types of non-small cell lung cancer. Because they differ on the basis of histopathological and clinical characteristics and their relationship with smoking, their etiologies may be different; for example, different tumor suppressor genes may be related to the genesis of each type. We used microarray data to construct three regulatory networks to identify potential genes related to lung adenocarcinoma and squamous cell carcinoma and investigated the similarity and specificity of them. In the network, some of the observed transcription factors and target genes had been previously proven to be related to lung adenocarcinoma and squamous cell carcinoma. We also found some new transcription factors and target genes related to SCC. The results demonstrated that regulatory network analysis is useful in connection analysis between lung adenocarcinoma and squamous cell carcinoma.

• 대한두경부종양학회지
• /
• 제32권2호
• /
• pp.69-72
• /
• 2016

Lung cancer is one of high mortality malignancy. It is known that skin metastasis from lung cancer is uncommon. We report a very rare case of finger tip metastasis from double primary cancer of the lung and lower lip. A 79 year-old man diagnosed with non small cell lung cancer presented with protruding solid mass in his lower lip. It showed central necrosis with purulent discharge. It had appeared rapidly growing features. Simultaneously, another solid mass accompanying painful swelling without skin lesion was found in his left middle finger tip. Both two solid masses were moderately differentiated squamous cell carcinomas. Lower lip mass was a primary cancer, while middle finger tip mass was diagnosed with clinically metastatic cancer from lung or lower lip, which means that it had double primary cancer origin.

• Journal of Chest Surgery
• /
• 제32권2호
• /
• pp.151-157
• /
• 1999

배경: 많은 실험적인 연구에서 종양 조직 내의 아포프토시스와 미세 혈관의 생성은 서로 반비례한다고 보고된다. 비소세포 폐암 조직내에서 두 수치의 관계를 조사하여 보았다. 대상 및 방법:조직내의 아포프토시스의 정도는 deoxynucleotidyl trasferase방법으로(Apop Tag In Situ Apoptosis Detection Kit, ONCOR) 측정하였고, 종양내 미세 혈관 밀도는 항 CD 31 항체를 이용하였다. 결과:아포프토시스 지수와 종양내 미세 혈관 밀도 사이에는 통계적으로 유의하게 역 상관관계가 있었다(p = 0.047). 결론: 비소세포 폐암종에서 아포프토시스와 미세 혈관 생성의 정도는 서로 연관이 있다고에 할 수있다. 그리고 종양내의 신생 혈관의 생성이 종양내 아포프토시스의 억제에 기여한다고 유추 할 수 있다.